Launch week offerEnds in00h00m00s

annual Promonthly Pro

Kerstin Noëlle Vokinger

Has grant

Professor and Academic Chair for Regulation in Law, Medicine and Technology

University of Zurich

Switzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Switzerland

Recent Grants

Grant: Close

Improving Access to Cancer Drugs - A Regulatory and Empirical Analysis

Open Date: 2021-01-01

Close Date:

Articles (26)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (6)

James Hillis

Massachusetts General Hospital

UNITED STATES

View details

Raja-Elie E. Abdulnour

Editor-in-Chief, NEJM Journal Watch

UMass Medical School

UNITED STATES

View details

Miquel Serra-Burriel

Assistant Professor

University of Zurich

SWITZERLAND

View details

Ariadna Tibau Martorell

Brigham and Women's Hospital

UNITED STATES

View details

Joseph Ross

Professor

Yale University School of Medicine

UNITED STATES

View details

Reshma Ramachandran

Yale University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Kerstin Noëlle Vokinger

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (26)

Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs

Most-favoured-nation pricing for prescription drugs in US Medicare: a cohort study

High Cost of Cancer Medicines in the United States: Opportunities for Policy Reforms

The Effects of Compulsory Licensing: A Case Study of HIV Drugs

Review Duration and Therapeutic Value of Cancer Drugs Granted Priority Versus Nonpriority Review in the United States, European Union, and Switzerland (2010-2024)

New Medicare Payment Policy on Drug Shortages

Authorization of prognostic AI medical devices

Regulation of AI: Learnings from Medical Education

Therapeutic benefit of the most expensive drugs covered by Medicare and Medicaid

Differences Between Trial Populations and Approved Label Populations of New Drugs in the United States and Europe (2012 to 2023)

The Risks of Pharmaceutical Tariffs for Generic Drug Availability

The Rise of Drug Innovation in China — Implications for Patient Access in the United States and Globally

The importance of high-quality evidence supporting cancer drug approvals

Generic competition and price developments in the USA, Germany and Switzerland (2007–2023): a longitudinal observational study

Proposed Policy Changes to Cancer Care and Oncologic Drug Reimbursement: Exploring the Rationale and Anticipating the Consequences

Time From Approval to Reimbursement of New Drugs: A Comparative Analysis Between the United States, England, Germany, France, and Switzerland (2011–2022)

Access to GLP-1 Weight Loss Drugs in the US, Canada, Switzerland, and Germany

Drug Prices After Patent Expirations in High-Income Countries and Implications for Cost-Effectiveness Analyses

Shortages of essential cancer medicines: who is responsible and what are the possible solutions?

AI Devices in Neurology—Moving From Diagnosis to Prognosis

Do Managed Entry Agreements Contribute to Lower Pharmaceutical Spending?

Development Pipeline and Geographic Representation of Trials for Artificial Intelligence/Machine Learning–Enabled Medical Devices (2010 to 2023)

Development Pipeline and Geographic Representation of Trials for Artificial Intelligence/Machine Learning–Enabled Medical Devices (2010 to 2023)

Defining ‘therapeutic value’ of medicines: a scoping review

Approval and therapeutic value of gene therapies in the US and Europe

Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020

Collaborators (6)

James Hillis

Raja-Elie E. Abdulnour

Miquel Serra-Burriel

Ariadna Tibau Martorell

Joseph Ross

Reshma Ramachandran

Make your next move.